

ASX Release

Apiam Animal Health Limited

(ASX: AHX)

4 December 2020

Appendix 3Y – Dr Chris Richards

An Appendix 3Y for Dr Richards is **attached**.

Apiam Animal Health Limited (ASX: AHX) (the “**Company**”) advises that:

1. The delay in lodgement of the Appendix 3Y notice was due to an internal administrative oversight.
2. The Company considers its existing arrangements are adequate to ensure it meets its disclosure obligations under ASX Listing Rule 3.19A and the late lodgement of the Appendix 3Y notice was an isolated incident. The Company is mindful of its disclosure obligations under ASX Listing Rule 3.19A.1 and 3.19A.2. The directors are also aware of their personal obligations involving the Company’s securities.

This announcement is authorised for release by the Chairman of the Board of Directors.

For further information, please contact:

Dr Chris Richards
Managing Director
Apiam Animal Health Limited
chris@apiam.com.au

About Apiam Animal Health Limited

Apiam Animal Health is positioned in the Australian market as a vertically integrated animal health business providing a range of products and services to Production and Mixed animals. Apiam Animal Health’s strategy is to service Production and Mixed animals throughout their lifecycle, including the provision of veterinary services, ancillary services, genetics, wholesale and retail of related products, together with technical services related to food-chain security.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	APIAM ANIMAL HEALTH LIMITED
ABN	50 604 961 024

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher RICHARDS
Date of last notice	06 November 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Beneficiary of CJR Super Company Pty Ltd as trustee for the C & J Richards Super Fund and CJOEA Family Company Pty Ltd as trustee for the Richards Family A/C.
Date of change	30 October 2020
No. of securities held prior to change	30,600,000 Shares 248,144 Performance Rights
Class	Fully Paid Ordinary Shares (Shares) Performance Rights
Number acquired	Nil
Number disposed	82,714 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	n/a
No. of securities held after change	30,600,000 Shares 165,430 Performance Rights

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Performance Rights
---	------------------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A